Litcius/Paper detail

Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways

Zihan Cui, Dapeng Li, Jun Zhao, Kai Chen

2022Free Radical Biology and Medicine33 citationsDOI

Topics & Concepts

CisplatinApoptosisCancer researchLung cancerEpidermal growth factor receptorDNA damageCell cycle checkpointCell growthReactive oxygen speciesCell cycleCytotoxicityCombination therapyPharmacologyProgrammed cell deathCancerChemistryBiologyMedicineChemotherapyOncologyIn vitroInternal medicineDNABiochemistryFerroptosis and cancer prognosisDrug Transport and Resistance MechanismsHistone Deacetylase Inhibitors Research
Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways | Litcius